Novartis Ag
- All
- News
- Videos
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
FDA Warns Novartis on Manufacturing Violations at Two India Plants
The US Food and Drug Administration warned Novartis AG last week after the Swiss firm was found in violation of manufacturing practices last year at two of its India drug-making plants, Novartis said.
-
US Court Finds Copaxone Patent Invalid Again: Natco Pharma
Mylan CEO Heather Bresch, in a separate statement, said: "We have stated all along that the '808 patent on Copaxone is invalid... We continue to remain very confident and look forward to bringing our product to market upon approval from the US Food and Drug Administration."
-
Novartis India Says Unaware of Any Delisting Plan
Earlier on Thursday, Bloomberg reported citing people with knowledge of the matter that Swiss drugmaker Novartis AG, which owns three quarters of Novartis India, was considering buying all the shares it didn't already own in the arm.
-
Novartis India Posts Two-Fold Jump in Q4 Profit
Pharmaceuticals firm Novartis India on Wednesday reported a jump of over two-fold in standalone net at Rs 51.94 crore for the quarter ended March, 2015.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
-
Ready to pay 'Reasonable' Royalty to Novartis AG: Cipla to High Court
Ready to pay 'Reasonable' Royalty to Novartis AG: Cipla to High Court
-
Novartis Posts Loss of Rs 1.18 Crore in Q3
Drugmaker Novartis India Ltd on Wednesday reported a net loss of Rs 1.18 crore for the third quarter that ended on December 31, 2014.
-
Novartis to Close Manufacturing Plant in Puerto Rico by 2019
Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Court Bars Cipla From Selling Copy of Novartis Respiratory Drug
The Delhi High Court, however, said that Cipla could file for a compulsory license if Novartis was not able to meet the demand. If granted, that would in effect breaks patent rights, making a cheaper version of the drug possible.
-
Court Order Restraining Drug Sale Disappointing: Cipla
Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
FDA Warns Novartis on Manufacturing Violations at Two India Plants
The US Food and Drug Administration warned Novartis AG last week after the Swiss firm was found in violation of manufacturing practices last year at two of its India drug-making plants, Novartis said.
-
US Court Finds Copaxone Patent Invalid Again: Natco Pharma
Mylan CEO Heather Bresch, in a separate statement, said: "We have stated all along that the '808 patent on Copaxone is invalid... We continue to remain very confident and look forward to bringing our product to market upon approval from the US Food and Drug Administration."
-
Novartis India Says Unaware of Any Delisting Plan
Earlier on Thursday, Bloomberg reported citing people with knowledge of the matter that Swiss drugmaker Novartis AG, which owns three quarters of Novartis India, was considering buying all the shares it didn't already own in the arm.
-
Novartis India Posts Two-Fold Jump in Q4 Profit
Pharmaceuticals firm Novartis India on Wednesday reported a jump of over two-fold in standalone net at Rs 51.94 crore for the quarter ended March, 2015.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
-
Ready to pay 'Reasonable' Royalty to Novartis AG: Cipla to High Court
Ready to pay 'Reasonable' Royalty to Novartis AG: Cipla to High Court
-
Novartis Posts Loss of Rs 1.18 Crore in Q3
Drugmaker Novartis India Ltd on Wednesday reported a net loss of Rs 1.18 crore for the third quarter that ended on December 31, 2014.
-
Novartis to Close Manufacturing Plant in Puerto Rico by 2019
Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Court Bars Cipla From Selling Copy of Novartis Respiratory Drug
The Delhi High Court, however, said that Cipla could file for a compulsory license if Novartis was not able to meet the demand. If granted, that would in effect breaks patent rights, making a cheaper version of the drug possible.
-
Court Order Restraining Drug Sale Disappointing: Cipla
Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.
